Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus Olaparib in resectable urothelial bladder cancer
NCT03534492Phase 2Completed
- Sponsor
- SOGUG
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, olaparib in bladder cancer, sponsored by SOGUG. Started Nov 2018; status: completed.
02
Drugs
durvalumabolaparib
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03534492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03534492.